58 related articles for article (PubMed ID: 6151361)
21. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling.
Balani SK; Li P; Nguyen J; Cardoza K; Zeng H; Mu DX; Wu JT; Gan LS; Lee FW
Drug Metab Dispos; 2004 Oct; 32(10):1092-5. PubMed ID: 15217988
[TBL] [Abstract][Full Text] [Related]
22. Rhenium tricarbonyl core complexes of thymidine and uridine derivatives.
Wei L; Babich J; Eckelman WC; Zubieta J
Inorg Chem; 2005 Apr; 44(7):2198-209. PubMed ID: 15792454
[TBL] [Abstract][Full Text] [Related]
23. Use of pharmacokinetics in veterinary medicine. Article. II: Volume, clearance, and half-life.
Martinez MN
J Am Vet Med Assoc; 1998 Oct; 213(8):1122-7. PubMed ID: 9787378
[No Abstract] [Full Text] [Related]
24. Chronopharmacokinetics of valproic acid following constant-rate administration in mice and influence of feeding schedule.
Song JG; Ohdo S; Ogawa N
Zhongguo Yao Li Xue Bao; 1995 Mar; 16(2):113-7. PubMed ID: 7597908
[TBL] [Abstract][Full Text] [Related]
25. Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction.
Bouligand J; Deroussent A; Simonnard N; Opolon P; Morizet J; Connault E; Daudigeos E; Re M; Paci A; Vassal G
Drug Metab Dispos; 2007 Feb; 35(2):306-14. PubMed ID: 17132762
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data.
Izumi T; Hosiyama K; Enomoto S; Sasahara K; Sugiyama Y
J Pharmacol Exp Ther; 1997 Mar; 280(3):1392-400. PubMed ID: 9067328
[TBL] [Abstract][Full Text] [Related]
27. [Genesis and metabolic fate of the twocarbon acids glycollic, glyoxylic and oxalic acids in the plant; literature review].
REINBOTHE H
Pharmazie; 1958 Nov; 13(11):693-703 contd. PubMed ID: 13623416
[No Abstract] [Full Text] [Related]
28. Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice.
Nnane IP; Njar VC; Brodie AM
Cancer Chemother Pharmacol; 2003 Jun; 51(6):519-24. PubMed ID: 12715204
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
[TBL] [Abstract][Full Text] [Related]
30. [Advances and related issues in the use of in vitro methods to predict metabolic clearance rate of new drugs].
Zhang Q; Wang GJ
Yao Xue Xue Bao; 2007 Oct; 42(10):1023-8. PubMed ID: 18229605
[TBL] [Abstract][Full Text] [Related]
31. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats.
Gandhi V; Chen W; Ayres M; Rhie JK; Madden TL; Newman RA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):85-94. PubMed ID: 12172971
[TBL] [Abstract][Full Text] [Related]
32. Chemoselective hydrazone formation between HYNIC-functionalized peptides and (18)F-fluorinated aldehydes.
Bruus-Jensen K; Poethko T; Schottelius M; Hauser A; Schwaiger M; Wester HJ
Nucl Med Biol; 2006 Feb; 33(2):173-83. PubMed ID: 16546671
[TBL] [Abstract][Full Text] [Related]
33. In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice.
Sugamori KS; Brenneman D; Grant DM
Drug Metab Dispos; 2006 Oct; 34(10):1697-702. PubMed ID: 16815960
[TBL] [Abstract][Full Text] [Related]
34. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice.
Burlingame RW; Volzer MA; Harris J; Du Clos TW
J Immunol; 1996 Jun; 156(12):4783-8. PubMed ID: 8648125
[TBL] [Abstract][Full Text] [Related]
35. Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows.
Bregante MA; Saez P; Aramayona JJ; Fraile L; Garcia MA; Solans C
Am J Vet Res; 1999 Sep; 60(9):1111-6. PubMed ID: 10490081
[TBL] [Abstract][Full Text] [Related]
36. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.
Takagi A; Masuda H; Takakura Y; Hashida M
J Pharmacol Exp Ther; 1995 Nov; 275(2):537-43. PubMed ID: 7473136
[TBL] [Abstract][Full Text] [Related]
37. Tissue distribution kinetics of a new nonsteroidal 5 alpha-reductase [correction of 5 A-reductase] inhibitor, 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-YL ]-butyric acid, in rats.
Katashima M; Yamamoto K; Haraguchi K; Tokuma Y; Hata T; Sawada Y; Iga T
Drug Metab Dispos; 1997 Sep; 25(9):1051-8. PubMed ID: 9311620
[TBL] [Abstract][Full Text] [Related]
38. Technetium-99m-GSA clearance in mice under long-term dietary restriction.
Kouda K; Kohno H; Nakamura H; Ha-Kawa SK; Sonoda Y; Iki M
Ann Nucl Med; 2009 Feb; 23(2):123-9. PubMed ID: 19225934
[TBL] [Abstract][Full Text] [Related]
39. Prediction of human pharmacokinetics - renal metabolic and excretion clearance.
Fagerholm U
J Pharm Pharmacol; 2007 Nov; 59(11):1463-71. PubMed ID: 17976256
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of 3-[Bis(2-hydroxyethyl)amino]acetophenone-(4,5- diphenyloxazol-2-yl)hydrazone (ZIMET 98/69) in mice.
Amlacher R; Ulbricht H
Acta Virol; 1984 Sep; 28(5):445. PubMed ID: 6151361
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
